Eli Lilly and Company $LLY Shares Bought by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC has increased its stake in Eli Lilly and Company by 6.3%, now holding 1,510,205 shares valued at approximately $1.25 billion, making it the 8th largest position in their portfolio.
• In the last quarter, several institutional investors significantly boosted their holdings in Eli Lilly, with PNC Financial Services increasing its stake by 97.5% and GAMMA Investing raising theirs by over 103,800%.
• Eli Lilly reported higher-than-expected quarterly earnings of $6.31 per share, surpassing analysts' estimates, and announced a quarterly dividend of $1.50 per share, translating to an annual yield of 0.8%.

Voya Investment Management LLC lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,510,205 shares of the company's stock after buying an additional 89,167 shares during the period. Eli Lilly and Company makes up about 1.4% of Voya Investment Management LLC's investment portfolio, making the stock its 8th biggest position. Voya Investment Management LLC owned approximately 0.16% of Eli Lilly and Company worth $1,246,687,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. WestEnd Advisors LLC lifted its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department boosted its holdings in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $43,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 0.2%

Shares of NYSE:LLY traded down $1.38 during trading on Friday, hitting $754.90. The company's stock had a trading volume of 2,195,977 shares, compared to its average volume of 3,737,676. The company has a market capitalization of $714.48 billion, a PE ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. The business has a 50 day moving average price of $741.03 and a two-hundred day moving average price of $776.40. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $942.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the company earned $3.92 EPS. The company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LLY shares. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Leerink Partners reissued a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $941.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.